Optimizing management of distal ulcerative colitis

References

• Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 255–81
   PubMed Web of Science ®Google Scholar
• Jewell DP. Ulcerative colitis. In: Sleisenger MH, Fordtran, JS. Gastrointestinal and liver disease. 7th ed. PhiladelphiaUSA: Saunders; 2002. pp 2039–67.
   Google Scholar
• Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003; 124: 521–36
   PubMed Web of Science ®Google Scholar
• Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol 2001; Suppl 234: 29–40
   Google Scholar
• Ahmad T, Marshall S, Jewell D. Genotype-based phenotyping heralds a new taxonomy for inflammatory bowel disease. Curr Opin Gastroenterol 2003; 19: 327–35
   PubMedGoogle Scholar
• Logan RF. Inflammatory bowel disease incidence: up, down or unchanged?. Gut 1998; 42: 309–11
   PubMed Web of Science ®Google Scholar
• Jewell DP. Ulcerative colitis. In: Oxford Textbook of Medicine. 3rd ed. OxfordUK: Oxford University Press; 1996. pp 1943–51.
   Google Scholar
• Tysk C, Järnerot G. Ulcerative proctocolitis in Örebro, Sweden. A retrospective epidemiologic study, 1963–1987. Scand J Gastroenterol 1992; 27: 945–50
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative proctitis in central Sweden 1965–1983. A population-based epidemiological study. Dig Dis Sci 1991; 36: 97–102
   PubMedGoogle Scholar
• Bjornsson S, Johannsson JH. Inflammatory bowel disease in Iceland, 1990–1994: a prospective, nationwide, epidemiological study. Eur J Gastroenterol Hepatol 2000; 12: 31–8
   PubMed Web of Science ®Google Scholar
• Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690–7
   PubMed Web of Science ®Google Scholar
• Pica R, Paoluzi OA, Iacopini F, Marcheggiano A, Crispino P, Rivera M, et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis 2004; 10: 731–6
   PubMed Web of Science ®Google Scholar
• Meucci G, Vecchi M, Astegiano M, Beretta L, Cesari P, Dizioli P, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol 2000; 95: 469–73
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in the extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996; 31: 260–6
   PubMed Web of Science ®Google Scholar
• Hyams J, Davis P, Lerer T, Colletti RB, Bousvaros A, Leichtner A, et al. Clinical outcome of ulcerative proctitis in children. J Pediatr Gastroenterol Nutr 1997; 25: 149–52
   PubMedGoogle Scholar
• Bitton A. Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis. Semin Gastrointest Dis 2001; 12: 263–74
   PubMedGoogle Scholar
• Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol 1988; 83: 497–503
   PubMed Web of Science ®Google Scholar
• Hirohata S, Ohshima N, Yanagida T, Aramaki K. Regulation of human B cell function by sulfasalazine and its metabolites. Int Immunopharmacol 2002; 2: 631–40
   PubMed Web of Science ®Google Scholar
• Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappa B in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000; 95: 3452–7
   PubMed Web of Science ®Google Scholar
• Liptay S, Bachem M, Hacker G, Adler G, Debatin KM, Schmid RM. Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol 1999; 128: 1361–9
   PubMed Web of Science ®Google Scholar
• Stevens C, Lipman M, Fabry S, Moscovitch-Lopatin M, Almawi W, Keresztes S, et al. 5-aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995; 272: 399–406
   PubMed Web of Science ®Google Scholar
• Greenfield SM, Punchard NA, Teare JP, Thompson RP. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 369–83
   PubMed Web of Science ®Google Scholar
• Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996;10 Suppl 2:81–90; discussion 91–2.
   PubMed Web of Science ®Google Scholar
• Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl 1996; 102: 9–21
   PubMedGoogle Scholar
• Travis SPL. The management of refractory distal colitis. Proc R Coll Physicians Edinb 2001; 31: 222–8
   Google Scholar
• Misiewicz JJ, Lennard-Jones JE, Connell AM, Baron JH, Avery-Jones F. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; 1: 185–8
   Web of Science ®Google Scholar
• Kamm MA. Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther 2002; 16 Suppl 4: 21–4
   PubMedGoogle Scholar
• Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002; 4: CD000544
   Google Scholar
• Paoluzi OA, Iacopini F, Pica R, Crispino P, Marcheggiano A, Consolazio A, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year followup study. Aliment Pharmacol Ther 2005; 21: 1111–9
   PubMed Web of Science ®Google Scholar
• Travis SP, Tysk C, de Silva HJ, Sandberg-Gertzen H, Jewell DP, Jarnerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994; 35: 1282–6
   PubMedGoogle Scholar
• Xu CT, Meng SY, Pan BR. Drug therapy for ulcerative colitis. World J Gastroenterol 2004; 10: 2311–7
   PubMed Web of Science ®Google Scholar
• Falasco G, Zinicola R, Forbes A. Review article: Immunosuppressants in distal ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 181–7
   PubMedGoogle Scholar
• Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627–30
   PubMed Web of Science ®Google Scholar
• Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 96–9
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, et al. Randomised controlled trial of azathioprine withdrawal in ulcerated colitis. Br Med J 1992; 305: 20–2
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9: 293–300
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Doldo P, Ranzi T, Sturniolo GC, Giglio LA, Annese V, et al. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 Study Group. Ital J Gastroenterol Hepatol 1999; 31: 677–84
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Ardizzone S, Benvenuti ME, Bianchi Porro G, Biasco G, Cesari P, et al. A new mesalazine enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicenter trial. Aliment Pharmacol Therap 1999; 13: 381–8
   PubMed Web of Science ®Google Scholar
• Aumais G, Lefebvre M, Tremblay C, Bitton A, Martin F, Giard A, et al. Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. Aliment Pharmacol Ther 2003; 17: 93–7
   PubMedGoogle Scholar
• Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263–76
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, Ferretti M, Brignola C, Miglioli M, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998; 41: 93–7
   PubMed Web of Science ®Google Scholar
• Danielsson A, Lofberg R, Persson T, Salde L, Schioler R, Suhr O, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992; 27: 9–12
   PubMed Web of Science ®Google Scholar
• Lamers CB, Wagtmans MJ, van der Sluys Veer A, van Hogezand RA, Griffioen G. Budesonide in inflammatory bowel disease. Neth J Med 1996; 48: 60–3
   PubMedGoogle Scholar
• Lindgren S, Lofberg R, Berghom L, Hellblom M, Carling L, Ung KA, et al. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol 2002; 37: 705–10
   PubMed Web of Science ®Google Scholar
• The Danish 5-ASA Group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Dig Dis Sci 1987;32:598–602.
   PubMedGoogle Scholar
• Farup PG, Hovde O, Halvorsen FA, Raknerud N, Brodin U. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol 1995; 30: 164–70
   PubMed Web of Science ®Google Scholar
• Gionchetti P, D'Arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol 2005; 39: 291–7
   PubMed Web of Science ®Google Scholar
• Brown J, Haines S, Wilding IR. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy. Aliment Pharmacol Ther 1997; 11: 685–91
   PubMedGoogle Scholar
• Chapman NJ, Brown ML, Phillips SF, Tremaine WJ, Schroeder KW, Dewanjee MK, et al. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin Proc 1992; 67: 245–8
   PubMedGoogle Scholar
• Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tabanelli GM, Miglioli M, et al. 5-aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?. J Clin Gastroenterol 1988; 10: 406–9
   PubMed Web of Science ®Google Scholar
• Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000; 95: 1749–54
   PubMed Web of Science ®Google Scholar
• Ryde M, Sandberg-Gertzen H, Järnerot G, Lauritsen K, Rask-Madsen J, Ahnfelt NO. Is 5-aminosalicyclic acid delivered directly to the colon by olsalazine?. Scand J Gastroenterol 1988; 23 Suppl 148: 104–6
   Google Scholar
• Sandberg-Gertzen H, Ryde M, Järnerot G. Absorption and excretion of a single dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol 1983; 18: 107–11
   PubMed Web of Science ®Google Scholar
• Campbell DES, Berglindh T. Pharmacology of olsalazine. Scand J Gastroenterol 1988; 23 Suppl 148: 7–12
   Google Scholar
• Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001; 48: 571–7
   PubMed Web of Science ®Google Scholar
• Rasmussen SN, Bondesen S, Hvidberg EF, Honoré Hansen S, Binder V, Halskov S, et al. 5-aminosalicyclic acid in a slow-release preparation: bioavailability, plasma level and excretion in humans. Gastroenterology 1982; 83: 1062–70
   PubMed Web of Science ®Google Scholar
• Stærk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271–6
   PubMedGoogle Scholar
• Ewe K, Becker K, Ueberschaer B. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission. Z Gastroenterol 1996; 34: 225–9
   PubMedGoogle Scholar
• Gionchetti P, Campieri M, Venturi A, Rizzello F, Feretti M, Brignola C, et al. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Aliment Pharmacol Ther 1996; 10: 601–5
   PubMedGoogle Scholar
• Stretch GL, Campbell BJ, Dwarakanath AD, Yaqoob M, Stevenson A, Morris AI, et al. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment Pharmacol Ther 1996; 10: 941–7
   PubMed Web of Science ®Google Scholar
• Tzivras M, Konstandinidis A, Hatzis G, Paraskeva K, Skandalis N, Archimandritis A. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Eur J Gastroenterol Hepatol 1997; 9: 729–30
   PubMedGoogle Scholar
• Mahmud N, Weir DG, Kelleher D. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicylic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease. Ir J Med Sci 1999; 168: 228–32
   PubMed Web of Science ®Google Scholar
• Stoa-Birketvedt G, Florholmen J. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. Aliment Pharmacol Ther 1999; 13: 357–61
   PubMedGoogle Scholar
• Kruis W, Brandes JW, Schreiber S, Theuer D, Krakamp B, Schütz E, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 707–13
   PubMed Web of Science ®Google Scholar
• Mansfield JC, Giaffer MH, Cann PA, Holdsworth CD, Thornton PC. Is high-dose balsalazide better than sulphasalazine in initial management of active ulcerative colitis?. Gut 1991; 32: A1217
   Google Scholar
• Green JRB, Swan CHJ, Rowlinson AE, Gibson JA, Brown P, Kerr GD, et al. Sulphasalazine or high-dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomised trial. Gastroenterology 1993; 104: A709
   PubMedGoogle Scholar
• Green JRB, Swan CHJ, Rowlinson AE, Gibson JA, Brown P, Kerr GD, et al. High-dose balsalazide compared with sulphasalazine in the treatment of acute relapse in ulcerative colitis. Gut 1991; 32: A1217
   Google Scholar
• Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 1998; 114: 15–22
   PubMed Web of Science ®Google Scholar
• Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johansen J, et al. Balsalazide is superior to mesalamine in time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97: 3078–86
   PubMed Web of Science ®Google Scholar
• Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988; 29: 835–7
   PubMed Web of Science ®Google Scholar
• Kruis W, Judmaier G, Kayasseh L, Stolte M, Theuer D, Scheurlen C, et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 391–6
   PubMedGoogle Scholar
• Nilsson Å, Danielsson Å, Löfberg R, Beno P, Bergman L, Fausa O, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol 1995; 90: 381–7
   PubMedGoogle Scholar
• Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PWN, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992; 339: 1279–81
   PubMed Web of Science ®Google Scholar
• McIntyre PB, Rodrigues CA, Lennard-Jones JE, Barrison IG, Walker JG, Baron JH, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther 1988; 2: 237–43
   PubMed Web of Science ®Google Scholar
• Kruis W, for the German Colazide Study Group. A comparison of two different doses of balsalazide and one dose of mesalazine in chronic treatment of ulcerative colitis. Gastroenterology 1998;114:A1014.
   Google Scholar
• Kane S, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalazine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929–33
   PubMed Web of Science ®Google Scholar
• BRX Global Research Services. A survey of attitudes and experiences of individuals with inflammatory bowel disease. First draft of a report prepared for the Crohn's and Colitis Foundation of America, 2003.
   Google Scholar
• Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191–8
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Petrillo M, Antonacci CM, Bianchi Porro G. Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis: a randomized single-blind comparative study. Aliment Pharmacol Ther 1996; 10: 957–60
   PubMedGoogle Scholar
• Bjorck S, Dahlstrom A, Ahlman H. Treatment of distal colitis with local anaesthetic agents. Pharmacol Toxicol 2002; 90: 173–80
   PubMedGoogle Scholar
• Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J (Clin Res Ed) 1985; 284: 706
   Google Scholar
• Benoni D, Nilsson A. Smoking habits in patients with inflammatory bowel disease. Scand J Gastroenterol 1984; 19: 824–30
   PubMed Web of Science ®Google Scholar
• McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2004; 4: CD004722
   Google Scholar
• Guslandi M, Frego R, Viale E, Testoni PA. Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. Can J Gastroenterol 2002; 16: 293–6
   PubMedGoogle Scholar
• Ohkusa T, Sato N. Antibacterial and antimycobacterial treatment for inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 340–51
   PubMedGoogle Scholar
• Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 207–15
   PubMed Web of Science ®Google Scholar
• Järnerot G. Clinical tolerance of olsalazine. Scand J Gastroenterol 1988; 23 Suppl 148: 21–3
   Google Scholar
• Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 647–62
   PubMed Web of Science ®Google Scholar
• Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case control study. Aliment Pharmacol Ther 2000; 14: 145–53
   PubMed Web of Science ®Google Scholar
• Sandberg-Gertzen H, Järnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology 1986; 90: 1024–30
   PubMed Web of Science ®Google Scholar
• Singer MV, Schmaußer SH, Schönfeld G. Efficacy and tolerability of olsalazine (Dipentum) in the treatment of patients with ulcerative colitis: results of a field study. Hepato gastroenterology, In press.
   Google Scholar
• Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004; 43: 803–21
   PubMed Web of Science ®Google Scholar
• Bebb JR, Logan RP. Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?. Aliment Pharmacol Ther 2001; 15: 1843–9
   PubMedGoogle Scholar
• Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249–52
   PubMed Web of Science ®Google Scholar
• Lofberg R. Combination therapy in active distal colitis: more studies are warranted. Eur J Gastroenterol Hepatol 1996; 8: 541–2
   PubMedGoogle Scholar
• Mantzaris GJ, Sfakianakis M, Archvalis E, Petraki K, Christidou A, Karagiannidis A, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004; 99: 1122–8
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805–11
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–76
   PubMed Web of Science ®Google Scholar
• Farrell RJ. Epidermal growth factor for ulcerative colitis. N Engl J Med 2003; 349: 395–7
   PubMed Web of Science ®Google Scholar
• Myers KJ, Murthy S, Flanigan A, Witchell DR, Butler M, Murray S, et al. Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. J Pharmacol Exp Ther 2003; 304: 411–24
   PubMed Web of Science ®Google Scholar
• Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999; 354: 635–9
   PubMed Web of Science ®Google Scholar
• Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103–8
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417–9
   PubMed Web of Science ®Google Scholar
• Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R, et al. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005; 34: 966–71
   Google Scholar
• Duan RD. Anticancer compounds and sphingolipid metabolism in the colon. In vivo 2005; 19: 293–300
   PubMed Web of Science ®Google Scholar
• Schofield PF, Manson JM. Indications for and results of operation in inflammatory bowel disease. J R Soc Med 1986; 79: 593–5
   PubMed Web of Science ®Google Scholar
• Adam D, Adam J, Price H. An analysis of an inflammatory bowel disease practice in an urban community hospital. Can J Gastroenterol 2000; 14: 483–8
   PubMedGoogle Scholar
• Frieri G, Pimpo M, Galletti B, Palumbo G, Corrao G, Latella G, et al. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 2005; 37: 92–6
   PubMedGoogle Scholar